Premium
Are induced pluripotent stem cells the future of cell‐based regenerative therapies for spinal cord injury?
Author(s) -
Salewski Ryan P.F.,
Eftekharpour Eftekhar,
Fehlings Michael G.
Publication year - 2010
Publication title -
journal of cellular physiology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.529
H-Index - 174
eISSN - 1097-4652
pISSN - 0021-9541
DOI - 10.1002/jcp.21995
Subject(s) - induced pluripotent stem cell , regenerative medicine , spinal cord injury , embryonic stem cell , stem cell , medicine , neuroscience , transplantation , cell therapy , stem cell therapy , neural stem cell , regeneration (biology) , bioinformatics , spinal cord , biology , surgery , microbiology and biotechnology , biochemistry , gene
Despite advances in medical and surgical care, current clinical therapies for spinal cord injury (SCI) are limited. During the last two decades, the search for new therapies has been revolutionized by the discovery of stem cells, inspiring scientists and clinicians to search for stem cell‐based reparative approaches for many disorders, including neurotrauma. Cell‐based therapies using embryonic and adult stem cells in animal models of these disorders have provided positive outcome results. However, the availability of clinically suitable cell sources for human application has been hindered by both technical and ethical issues. The recent discovery of induced pluripotent stem (iPS) cells holds the potential to revolutionize the field of regenerative medicine by offering the option of autologous transplantation, thus eliminating the issue of host rejection. Herein, we will provide the rationale for the use of iPS cells in SCI therapies. In this review, we will evaluate the recent advancements in the field of iPS cells including their capacity for differentiation toward neural lineages that may allow iPS cells transplantation in cell‐based therapy for spinal cord repair. J. Cell. Physiol. 222: 515–521, 2010. © 2009 Wiley‐Liss, Inc.